Literature DB >> 12606395

Immunocontraception is induced in BALB/c mice inoculated with murine cytomegalovirus expressing mouse zona pellucida 3.

Megan L Lloyd1, Geoffrey R Shellam, John M Papadimitriou, Malcolm A Lawson.   

Abstract

Immunocontraception, the prevention of oocyte fertilization through immunological means, could potentially be used to control plaguing mouse populations in Australia. This paper describes the construction of a mouse-specific betaherpesvirus, murine cytomegalovirus, which has been engineered to express the murine zona pellucida 3 (ZP3) gene. A single inoculation of this recombinant virus resulted in almost complete infertility, persistent anti-ZP3 antibody production, and profound changes to ovarian morphology in BALB/c mice in the absence of significant virus replication during the acute phase of infection. Murine cytomegalovirus may prove to be useful as a vector for the delivery of a mouse-specific immunocontraceptive agent to target populations of wild mice in the field.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606395     DOI: 10.1095/biolreprod.102.012880

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  18 in total

Review 1.  Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.

Authors:  Michael Quinn; Dan A Erkes; Christopher M Snyder
Journal:  Immunotherapy       Date:  2016-01-20       Impact factor: 4.196

Review 2.  Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity.

Authors:  Dan A Erkes; Nicole A Wilski; Christopher M Snyder
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

3.  Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception.

Authors:  Alec J Redwood; Martin Messerle; Nicole L Harvey; Christopher M Hardy; Ulrich H Koszinowski; Malcolm A Lawson; Geoffrey R Shellam
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.

Authors:  Christopher M Snyder; Kathy S Cho; Elizabeth L Bonnett; Serani van Dommelen; Geoffrey R Shellam; Ann B Hill
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

5.  Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus.

Authors:  L M Smith; A R McWhorter; L L Masters; G R Shellam; A J Redwood
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

6.  Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.

Authors:  Guangwu Xu; Tameka Smith; Finn Grey; Ann B Hill
Journal:  Biochem Biophys Res Commun       Date:  2013-06-27       Impact factor: 3.575

7.  IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity.

Authors:  Maria Pletneva; Hongni Fan; Jang-June Park; Vedran Radojcic; Chunfa Jie; Yanxing Yu; Camie Chan; Alec Redwood; Drew Pardoll; Franck Housseau
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

Review 8.  Milestones in contraceptive vaccines development and hurdles in their application.

Authors:  Satish Kumar Gupta; Abhinav Shrestha; Vidisha Minhas
Journal:  Hum Vaccin Immunother       Date:  2013-11-21       Impact factor: 3.452

9.  Granulocyte-macrophage colony-stimulating factor enhances the humoral immune responses of mouse zona pellucida 3 vaccine strategy based on DNA and protein coadministration in BALB/c mice.

Authors:  Zibirnisa Kadir; Xiaolin Ma; Jinyao Li; Fuchun Zhang
Journal:  Reprod Sci       Date:  2012-10-30       Impact factor: 3.060

Review 10.  Vaccines for immunological control of fertility.

Authors:  Satish K Gupta; Pankaj Bansal
Journal:  Reprod Med Biol       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.